| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Rosenheck, D Evans, L Herz, J Cramer, W Xu, J Thomas, W Henderson, D Charne. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophrenia bulletin. vol 25. issue 4. 2000-03-03. PMID:10667741. |
how long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. |
2000-03-03 |
2023-08-12 |
Not clear |
| R Rosenheck, D Evans, L Herz, J Cramer, W Xu, J Thomas, W Henderson, D Charne. How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia. Schizophrenia bulletin. vol 25. issue 4. 2000-03-03. PMID:10667741. |
a double-blind trial compared clozapine and haloperidol in patients with schizophrenia who were refractory to conventional antipsychotic medication and were hospitalized for 30 to 364 days at 15 veteran affairs medical centers during the year before study entry. |
2000-03-03 |
2023-08-12 |
Not clear |
| J G Kilian, K Kerr, C Lawrence, D S Celermaje. Myocarditis and cardiomyopathy associated with clozapine. Lancet (London, England). vol 354. issue 9193. 2000-02-29. PMID:10584719. |
clozapine is effective for resistant schizophrenia. |
2000-02-29 |
2023-08-12 |
Not clear |
| E Spina, A Avenoso, G Facciolà, M G Scordo, M Ancione, A G Madia, A Ventimiglia, E Perucc. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology. vol 148. issue 1. 2000-02-25. PMID:10663421. |
relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. |
2000-02-25 |
2023-08-12 |
Not clear |
| S Oerther, S Ahleniu. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat. The Journal of pharmacology and experimental therapeutics. vol 292. issue 2. 2000-02-22. PMID:10640312. |
it is suggested that stimulation of da d(1) receptors, presumably in the prefrontal cortex, is a distinguishing feature of clozapine responsible for its favorable profile on cognitive functioning in schizophrenia. |
2000-02-22 |
2023-08-12 |
rat |
| K S Earnst, S F Taylor, I C Smet, R S Goldman, R Tandon, S Beren. The effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia. Schizophrenia research. vol 40. issue 3. 2000-02-18. PMID:10638864. |
the effects of typical antipsychotics, clozapine, and risperidone on neuropsychological test performance in schizophrenia. |
2000-02-18 |
2023-08-12 |
Not clear |
| P Tibbo, K Gendeman. Improvement of obsessions and compulsions with clozapine in an individual with schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 44. issue 10. 2000-02-15. PMID:10637686. |
improvement of obsessions and compulsions with clozapine in an individual with schizophrenia. |
2000-02-15 |
2023-08-12 |
Not clear |
| B Buur-Rasmussen, K Brøse. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9. issue 6. 2000-02-08. PMID:10625111. |
clozapine is an atypical antipsychotic drug that is mainly used for the treatment of refractory schizophrenia. |
2000-02-08 |
2023-08-12 |
Not clear |
| M Markianos, J Hatzimanolis, L Lykoura. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9. issue 6. 2000-02-08. PMID:10625122. |
we measured the plasma levels of testosterone (tst), lh, fsh, as well as of prolactin (prl) and cortisol (cort), in a group of male patients with schizophrenia during treatment with classical neuroleptics with no satisfactory therapeutic response (31 pts, age 30.3+/-8.5, range 18-50), and 6 weeks later, after switch to treatment with clozapine (clz) in doses from 100 to 600 mg daily (mean 328 mg). |
2000-02-08 |
2023-08-12 |
Not clear |
| G Gobbi, L Janir. Clozapine blocks dopamine, 5-HT2 and 5-HT3 responses in the medial prefrontal cortex: an in vivo microiontophoretic study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 10. issue 1. 2000-02-02. PMID:10647096. |
clozapine is an atypical antipsychotic drug active on both positive and negative symptoms of schizophrenia which has a unique serotonergic and dopaminergic profile. |
2000-02-02 |
2023-08-12 |
Not clear |
| M Velasco, A Luchsinge. Dopamine: pharmacologic and therapeutic aspects. American journal of therapeutics. vol 5. issue 1. 2000-01-31. PMID:10099036. |
clozapine is used for treating schizophrenia. |
2000-01-31 |
2023-08-12 |
Not clear |
| M Wudarsky, R Nicolson, S D Hamburger, L Spechler, P Gochman, J Bedwell, M C Lenane, J L Rapopor. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. Journal of child and adolescent psychopharmacology. vol 9. issue 4. 2000-01-28. PMID:10630453. |
the national institute of mental health patients--13 females, 22 males (mean age, 14.1+/-2.3 years; range, 9.1-19 years) with childhood onset schizophrenia (n = 32), or psychotic disorder not otherwise specified (nos) (n = 3) with onset of psychosis before age 13--were recruited for open or double-blind trials of haloperidol, clozapine, or olanzapine. |
2000-01-28 |
2023-08-12 |
Not clear |
| C R Ashby, R Y Wan. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse (New York, N.Y.). vol 24. issue 4. 2000-01-27. PMID:10638826. |
subsequently, clinical studies have shown that clozapine is effective in ameliorating the core symptoms, as well as the negative symptoms, in schizophrenia. |
2000-01-27 |
2023-08-12 |
Not clear |
| S M Dursun, A Szemis, H Andrews, M A Revele. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. Journal of psychiatry & neuroscience : JPN. vol 24. issue 5. 2000-01-20. PMID:10586536. |
the effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. |
2000-01-20 |
2023-08-12 |
Not clear |
| S M Dursun, A Szemis, H Andrews, M A Revele. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. Journal of psychiatry & neuroscience : JPN. vol 24. issue 5. 2000-01-20. PMID:10586536. |
to investigate the effects of 12 weeks of clozapine treatment on levels of cholesterol and related lipids in patients with schizophrenia. |
2000-01-20 |
2023-08-12 |
Not clear |
| J G Burke, S M Dursun, M A Revele. Refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine. Journal of psychiatry & neuroscience : JPN. vol 24. issue 5. 2000-01-20. PMID:10586537. |
refractory symptomatic schizophrenia resulting from frontal lobe lesion: response to clozapine. |
2000-01-20 |
2023-08-12 |
Not clear |
| A Szegedi, I Anghelescu, J Wiesner, S Schlegel, H Weigmann, S Härtter, C Hiemke, H Wetze. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry. vol 32. issue 4. 2000-01-19. PMID:10505485. |
addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. |
2000-01-19 |
2023-08-12 |
Not clear |
| E Stip, I Lussier, P Lalonde, A Luyet, J Fabia. [Atypical neuroleptics and selective attention]. L'Encephale. vol 25. issue 3. 1999-12-29. PMID:10434152. |
the aim of this study was to examine selective attention in patients with chronic and refractory schizophrenia who had been exposed for six months to atypical neuroleptic medications: risperidone or clozapine. |
1999-12-29 |
2023-08-12 |
Not clear |
| R E See, A A Fido, M Maurice, M M Ibrahim, G M Salam. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biological psychiatry. vol 45. issue 12. 1999-12-20. PMID:10376128. |
previous studies have shown an increase in plasma levels of norepinephrine (ne) after clozapine treatment of schizophrenia. |
1999-12-20 |
2023-08-12 |
Not clear |
| J P McEvoy, O Freudenreich, W H Wilso. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biological psychiatry. vol 46. issue 1. 1999-12-20. PMID:10394482. |
smoking and therapeutic response to clozapine in patients with schizophrenia. |
1999-12-20 |
2023-08-12 |
Not clear |